Literature DB >> 16126181

Decreased sensitivity to the effects of dopamine D1-like, but not D2-like, receptor antagonism in the posterior hypothalamic region/anterior ventral tegmental area on brain reward function during chronic exposure to nicotine in rats.

Adrie W Bruijnzeel1, Athina Markou.   

Abstract

Chronic administration of nicotine induces adaptations in central nervous system function to counteract nicotine's acute effects. When nicotine administration ceases, these adaptations remain unopposed and may lead to drug withdrawal. The present studies were conducted to assess the effects of chronic nicotine administration on dopamine D1- and D2-like receptor activity in the posterior hypothalamus/anterior ventral tegmental area (VTA). An intracranial self-stimulation discrete trial procedure that provides current intensity thresholds was used to provide a measure of brain reward function in rats. Previous studies showed that systemic administration of dopamine D1- or D2-like receptor antagonists induced elevations in brain reward thresholds in drug-free rats, indicative of a decrease in brain reward function. We show here that injections of the D1-like receptor antagonist SCH 23390 (1-4 microg total bilateral dose) into the posterior hypothalamus/anterior VTA differentially elevated brain reward thresholds in rats chronically treated with nicotine (9 mg/kg/day, salt) versus saline-treated rats. The nicotine-treated rats were less sensitive to the threshold elevating effects of D1-like receptor antagonism. By contrast, the D2-like receptor antagonist eticlopride (1-4 microg total bilateral dose) injected into the posterior hypothalamus/anterior VTA significantly elevated brain reward thresholds in saline- and nicotine-treated rats. No differential effect of eticlopride on brain reward thresholds in saline- and nicotine-treated rats was observed. Decreased sensitivity to D1-like receptor antagonism in the posterior hypothalamus/anterior VTA may partly mediate the development of tolerance to the reinforcing effects of nicotine and the manifestation of negative affective signs associated with cessation of nicotine administration.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16126181     DOI: 10.1016/j.brainres.2005.07.056

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Somatostatin-28 modulates prepulse inhibition of the acoustic startle response, reward processes and spontaneous locomotor activity in rats.

Authors:  Svetlana Semenova; Daniel Hoyer; Mark A Geyer; Athina Markou
Journal:  Neuropeptides       Date:  2010-10       Impact factor: 3.286

2.  Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats.

Authors:  Daria Rylkova; Jeffrey Boissoneault; Shani Isaac; Melissa Prado; Hina P Shah; Adrie W Bruijnzeel
Journal:  Neuropeptides       Date:  2008-05-12       Impact factor: 3.286

3.  An analysis of the rewarding and aversive associative properties of nicotine in the neonatal quinpirole model: Effects on glial cell line-derived neurotrophic factor (GDNF).

Authors:  Russell W Brown; Seth L Kirby; Adam R Denton; John M Dose; Elizabeth D Cummins; Wesley Drew Gill; Katherine C Burgess
Journal:  Schizophr Res       Date:  2017-03-14       Impact factor: 4.939

4.  Neuro-anatomic mapping of dopamine D1 receptor involvement in nicotine self-administration in rats.

Authors:  Brandon J Hall; Susan Slade; Cheyenne Allenby; Munir G Kutlu; Edward D Levin
Journal:  Neuropharmacology       Date:  2015-03-19       Impact factor: 5.250

5.  Metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP) microinfusions into the nucleus accumbens shell or ventral tegmental area attenuate the reinforcing effects of nicotine in rats.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-08-31       Impact factor: 5.250

6.  Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) study: the moderating role of smoking status and antipsychotic medications.

Authors:  Junghee Lee; Michael F Green; Monica E Calkins; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Gregory A Light; Keith H Nuechterlein; Allen D Radant; Larry J Seidman; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Neal R Swerdlow; Debby W Tsuang; Ming T Tsuang; Bruce I Turetsky; David L Braff
Journal:  Schizophr Res       Date:  2014-09-22       Impact factor: 4.939

Review 7.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

8.  Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine.

Authors:  Taryn E Grieder; Laurie H Sellings; Hector Vargas-Perez; Ryan Ting-A-Kee; Eric C Siu; Rachel F Tyndale; Derek van der Kooy
Journal:  Neuropsychopharmacology       Date:  2009-12-23       Impact factor: 7.853

9.  Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission.

Authors:  Roberto Ciccocioppo; Giordano de Guglielmo; Hongwu Li; Miriam Melis; Lucia Caffino; Quienwei Shen; Ana Domi; Fabio Fumagalli; Gregory A Demopulos; George A Gaitanaris
Journal:  J Neurosci       Date:  2021-06-01       Impact factor: 6.167

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.